C7, Human, mAb WU 4-15
The monoclonal antibody WU 4-15 recognizes C7, one of the components of the terminal complement complex (TCC), also know as the membrane attack complex (MAC). Proteolytic cleavage of C5 by C5 convertase generates C5b which initiates assembly of the C5b-9 MAC. This complex is assembled from five precursor molecules in the serum, finalized with the polymerization of C9 which accompanies insertion of the complex into the cell membrane causing cellular lysis. C7 occupies an important position in the TCC cascade. C7 undergoes a hydrophilic-amphiphilic transition following activation. It enables the developing MAC to bind directly to target cell membranes. C7 has been shown to exhibit genetic polymorphism. Polymorphonuclear leukocytes represent a major source of C7. The fact that inflammatory cells have the potential to secrete C7 suggests an important role for locally produced complement in the inflammatory process. The monoclonal antibody WU 4-15 identifies an specific allotype of C7: C7 M. 62% of the caucasians is homozygous for C7 M, 31% heterozygous. Antibody Wu 4-15 enables to quantify the contribution of locally synthesized C7 to the inflammatory process and to identify the allotype.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA